![Vivek Subbiah: Adding chemotherapy to cemiplimab at progression might provide a new second-line treatment for patients with advanced non-small-cell lung cancer.](https://oncodaily.com/pub/uploads/2023/08/Vivek-Subbiah-2-e1693431964565-1280x951.jpg)
Photo taken from Vivek Subbiah/Twitter
Aug 30, 2023, 17:46
Vivek Subbiah: Adding chemotherapy to cemiplimab at progression might provide a new second-line treatment for patients with advanced non-small-cell lung cancer.
In a post by Vivek Subbiah, the Chief Early-Phase Drug Development at Sarah Cannon Research Institute, on LinkedIn, it says:
“At 35 months’ follow-up, the survival benefit of cemiplimab for patients with advanced non-small-cell lung cancer was at least as pronounced as at 1 year, affirming its use as first-line monotherapy for this population. Adding chemotherapy to cemiplimab at progression might provide a new second-line treatment for patients with advanced non-small-cell lung cancer.”
For the article click here.
Source: Vivek Subbiah/LinkedIn